For thousands of people who have endured a bone marrow transplant, the relief of beating leukaemia or another blood cancer can be undercut by a brutal complication: graft-versus-host disease, or GvHD. The donor's immune cells, transplanted to rebuild the patient's bone marrow, can turn on their new host — attacking skin, gut, liver and lungs.
Around half of donor stem-cell transplant recipients go on to develop some form of GvHD, according to the UK blood cancer charity Anthony Nolan. For some it is mild and manageable. For others it is life-changing, and sometimes fatal.
Now, Scientific American reports that hope may be on the way. The US Food and Drug Administration could approve the first regulatory T cell therapy as soon as spring 2026 — a treatment designed to prevent GvHD before it begins.
What is a "peacekeeper" cell?
Regulatory T cells, known to scientists as Tregs, are the immune system's diplomats. Where other immune cells hunt down infections and tumours, Tregs have the opposite job: they hold the rest of the system in check, stopping it from attacking the body's own tissues.
The Nobel Assembly called them the immune system's "security guards" when it awarded the 2025 Nobel Prize in Physiology or Medicine to Mary Brunkow, Fred Ramsdell and Shimon Sakaguchi for their discoveries concerning peripheral immune tolerance — the mechanism by which Tregs keep the peace inside us.
Sakaguchi first identified the cells in the 1990s. Brunkow and Ramsdell later traced their development to a single gene, FOXP3, mutations of which cause a devastating childhood autoimmune condition called IPEX syndrome.
That foundational science, painstakingly built up over three decades, is now moving from the laboratory bench to the hospital ward.
From the bench to the bedside
The candidate therapy in front of the FDA uses purified Tregs alongside donor stem cells in bone marrow transplants, with the aim of damping down the immune attack that causes GvHD — without weakening the graft's ability to fight off any remaining cancer cells.
Scientific American notes that the spring 2026 window is a target rather than a guarantee. Regulatory timelines can and do slip; one leading candidate has already had its FDA review extended into the summer. But approval would mark the first time anywhere in the world that a Treg-based cellular medicine has reached patients outside of a clinical trial.
The implications stretch well beyond bone marrow transplants. Researchers are already testing Treg therapies for autoimmune diseases including type 1 diabetes, lupus and inflammatory bowel disease, and for the rejection of transplanted solid organs.
A British story too
The UK is not a bystander in this field. King's College London hosts one of Europe's leading Treg research groups, with work spanning liver, kidney and bone marrow transplantation. And the UK's Medicines and Healthcare products Regulatory Agency has authorised the world's first-in-human trial of a CAR-Treg therapy — an engineered version of the cells designed to localise inside a transplanted kidney and quietly suppress rejection.
Anthony Nolan, the charity that runs the UK's stem-cell register, has long campaigned for better treatments for patients living with chronic GvHD, describing recent therapeutic advances as a long-overdue "step forward" for a community that has been waiting decades.
Scottish patients, who travel to specialist transplant centres in Glasgow and Edinburgh, would expect any therapy approved by the FDA to follow in due course through the UK's own regulatory channels.
Cautious optimism
It is, in other words, a story to watch — carefully, and with the kind of cautious optimism that good science deserves. Decades of patient laboratory work, a Nobel Prize, and a generation of patients hoping that the body's quietest immune cells might finally be able to keep the peace where it matters most.
